We are very excited to receive recognition for PV Hawk. Not only is it an honor, but it shows the value and flexibility of Perficient’s enthusiasm for bringing common sense to complex problems and the success of our cross-functional teams that contributed to getting this solution out. For many years, I, along with many others, struggled to find ways to deliver digested pharmacovigilance (PV) data that would enable me to evaluate AE data, weigh the safety profile of the particular drug, look for new indications, and to provide meaningful input to cross-functional departments within an organization.
We Perficient, took up the challenge, and the result is PV Hawk. Its clean graphics and near real-time data loads (data is refreshed every 24 hrs) gives those responsible for looking after adverse events and product quality a truly useful tool with PV-centric, drill-down capabilities. No matter which part of the spectrum in drug safety you take part in or which type of drug-device or biologic, everyone in risk management, from manufacturing to post-market, can utilize this tool. It lends a holistic approach to safety surveillance – the way that it should be.
Accelerate Clinical Trials With AI and Real-Time Data Collaboration
Discover a unified clinical data review and collaboration solution that optimizes the integration and review of complex, ever-changing clinical data.
For example, while we were in the very early learning stages of COVID-19, PV Hawk offered the ability to drill down the data to take similar clinical pictures (i.e., cytokine storm in other critically ill patients) and to find historic PV data and drugs that might offer a therapeutic benefit. PV Hawk is more than just safety surveillance of AEs and PQCs; it is a powerful tool for clinical therapeutics when time is critical.
The PV Hawk team and I are very humbled and honored to receive this year’s MedTech award.
For a demo, more information on how your organization can use PV Hawk, or how we can perform risk management for you, please feel free to reach out to me.